ZV
$10.47
+0.31
(+3.05%)
As of Oct 20, 2026, 6:53 PM EDT
Price history
Zevra Therapeutics Inc (ZVRA) is trading up at $10.47 (+3.05%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Zevra Therapeutics Inc revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $0 | $12.8M | $13.3M | $28.6M | $10.2M | $27.5M | $23.6M | $106.5M |
| Growth (year over year) | — | — | — | — | +3.5% | +115.6% | −64.5% | +170.3% | −14.0% | +350.9% |
| Gross profit | — | — | $0 | $2.84M | — | $26.6M | $9.94M | $24.5M | $16.2M | $90.0M |
| Gross margin | — | — | — | 22.1% | — | 92.8% | 97.8% | 89.3% | 68.6% | 84.5% |
| Operating income | −$37.5M | −$33.4M | −$55.9M | −$20.3M | −$5.61M | $7.73M | −$42.6M | −$49.6M | −$87.0M | −$62.9M |
| Operating margin | — | — | — | −158.4% | −42.2% | 27.0% | −418.9% | −180.6% | −368.5% | −59.1% |
| Net income | −$16.5M | −$43.4M | −$56.5M | −$24.5M | −$12.8M | −$8.55M | −$26.8M | −$46.0M | −$105.5M | $83.2M |
| Net margin | — | — | — | −191.0% | −96.0% | −29.9% | −263.5% | −167.7% | −446.9% | 78.2% |
| EPS (diluted) | −$1.13 | −$2.96 | −$3.15 | −$13.23 | −$3.21 | −$2.11 | — | — | −$2.28 | $1.35 |
| Balance sheet | ||||||||||
| Cash and equivalents | $16.8M | $10.9M | $18.4M | $3.22M | $4.21M | $112.3M | $65.5M | $43.0M | $33.8M | $62.4M |
| Total assets | $84.9M | $52.5M | $26.7M | $10.5M | $11.2M | $132.9M | $115.3M | $172.3M | $178.1M | $284.7M |
| Total liabilities | $103.6M | $110.0M | $93.3M | $85.0M | $77.6M | $5.82M | $40.2M | $110.5M | $138.5M | $130.1M |
| Long-term debt | — | $92.7M | $81.4M | $77.3M | $67.7M | — | — | $5.07M | $59.5M | $61.9M |
| Shareholders' equity | −$18.7M | −$57.5M | −$66.6M | −$74.5M | −$66.4M | $101.7M | $75.1M | $61.9M | $39.7M | $154.7M |
| Cash flow | ||||||||||
| Operating cash flow | −$29.8M | −$33.1M | −$54.2M | −$23.7M | −$1.94M | $10.4M | −$18.7M | −$33.5M | −$69.7M | −$1.60M |
| Capital expenditure | $643.0K | $181.0K | $21.0K | $26.0K | $33.0K | $102.0K | $93.0K | $296.0K | $0 | $835.0K |
| Free cash flow | −$30.4M | −$33.3M | −$54.2M | −$23.8M | −$1.97M | $10.3M | −$18.8M | −$33.8M | −$69.7M | −$2.43M |
| Share buybacks | — | — | — | — | $0 | $2.81M | $4.72M | $3.45M | $0 | — |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.69M | — | $20.4M | $25.9M | $26.1M | $34.1M | $36.2M | $39.7M |
| Growth (year over year) | +27.6% | — | +495.6% | +481.7% | +605.4% | — | +77.5% | +53.3% |
| Gross profit | $1.39M | — | $19.1M | $13.5M | $24.8M | $32.6M | $34.3M | $38.1M |
| Gross margin | 37.7% | — | 93.4% | 52.2% | 95.2% | 95.5% | 94.8% | 96.2% |
| Operating income | −$27.3M | — | −$5.36M | −$71.0M | $4.14M | $9.31M | $52.1M | $16.8M |
| Operating margin | −739.0% | — | −26.3% | −274.5% | 15.9% | 27.3% | 144.0% | 42.3% |
| Net income | −$33.2M | — | −$3.10M | $74.7M | −$544.0K | $12.2M | $37.9M | $8.75M |
| Net margin | −899.2% | — | −15.2% | 288.7% | −2.1% | 35.6% | 104.6% | 22.1% |
| EPS (diluted) | −$0.69 | — | −$0.06 | $1.21 | −$0.01 | $0.21 | $0.60 | $0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $54.0M | $33.8M | $37.3M | $47.7M | $54.4M | $62.4M | $95.6M | $145.3M |
| Total assets | $191.6M | $178.1M | $172.7M | $256.3M | $270.1M | $284.7M | $278.6M | $302.7M |
| Total liabilities | $121.8M | $138.5M | $131.7M | $139.0M | $137.0M | $130.1M | $72.8M | $85.1M |
| Long-term debt | $58.9M | $59.5M | $60.1M | $60.7M | $61.3M | $61.9M | $0 | $0 |
| Shareholders' equity | $69.8M | $39.7M | $41.0M | $117.2M | $133.2M | $154.7M | $205.8M | $217.7M |
| Cash flow | ||||||||
| Operating cash flow | −$18.1M | — | −$8.22M | −$3.60M | $4.71M | $5.52M | $6.14M | $17.0M |
| Capital expenditure | $0 | — | $99.0K | $213.0K | $554.0K | −$31.0K | $35.0K | $217.0K |
| Free cash flow | −$18.1M | — | −$8.32M | −$3.81M | $4.16M | $5.55M | $6.11M | $16.8M |
| Share buybacks | $0 | — | — | — | — | — | — | — |
From Zevra Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Zevra Therapeutics Inc
- Headquarters
- Boston, Massachusetts From SEC filings, Oct 2026
Recent News (3)
-
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people livin…
-
Zevra Therapeutics president and CEO sells $224,948 in stock
Zevra Therapeutics president and CEO sells $224,948 in stock
-
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International